Doug made a passing comment to the effect of redeploying efforts (into US FDA application?) as a reason for the sales. If I heard correctly, this would pass the sniff test IMO given the ~60% headcount reduction they mentioned as part of the restructure, and that perhaps without US sales, Febridx top line may not stack up to carry business forward.
Hoping someone can confirm or correct what I heard?
AIMHO. DYOR.
LDX Price at posting:
11.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)